Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a report on Thursday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Salarius Pharmaceuticals presently has a consensus rating of “Sell”.

Check Out Our Latest Report on SLRX

Salarius Pharmaceuticals Price Performance

Shares of Salarius Pharmaceuticals stock opened at $0.83 on Friday. The stock has a market capitalization of $4.83 million, a price-to-earnings ratio of -0.02 and a beta of 0.40. The business has a 50-day moving average of $2.69 and a 200 day moving average of $7.10. Salarius Pharmaceuticals has a 12 month low of $0.71 and a 12 month high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($1.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

(Get Free Report)

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

Further Reading